[New drug approval: Olaparib - pancreatic cancer with BRCA germline mutation]

Marc Hilmi; Cindy Neuzillet

doi:10.1016/j.bulcan.2020.06.009

[New drug approval: Olaparib - pancreatic cancer with BRCA germline mutation]

Bull Cancer. 2020 Oct;107(10):961-962. doi: 10.1016/j.bulcan.2020.06.009. Epub 2020 Sep 14.

[Article in French]

Authors

Marc Hilmi¹, Cindy Neuzillet²

Affiliations

¹ Université de Versailles Saint-Quentin, institut Curie, département d'oncologie médicale, 35, rue Dailly, 92210 Saint-Cloud, France. Electronic address: hilmi.marc@gmail.com.
² Université de Versailles Saint-Quentin, institut Curie, département d'oncologie médicale, 35, rue Dailly, 92210 Saint-Cloud, France.

PMID: 32943226
DOI: 10.1016/j.bulcan.2020.06.009

No abstract available

Keywords: Adénocarcinome du pancréas; BRCA1/2; Homologous recombination; Inhibiteurs de PARP; PARP inhibitors; Pancreatic adenocarcinoma; Recombinaison homologue.

Publication types

Letter

MeSH terms

Carcinoma, Pancreatic Ductal / drug therapy
Carcinoma, Pancreatic Ductal / genetics
Carcinoma, Pancreatic Ductal / secondary*
Clinical Trials, Phase III as Topic
Drug Approval
Fatigue / chemically induced
Female
Genes, BRCA1*
Genes, BRCA2*
Germ-Line Mutation
Humans
Male
Multicenter Studies as Topic
Pancreatic Neoplasms / drug therapy*
Pancreatic Neoplasms / genetics
Phthalazines / adverse effects
Phthalazines / therapeutic use*
Piperazines / adverse effects
Piperazines / therapeutic use*
Poly(ADP-ribose) Polymerase Inhibitors / adverse effects
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use*
Treatment Outcome

Substances

Phthalazines
Piperazines
Poly(ADP-ribose) Polymerase Inhibitors
olaparib